Methods of improving nutritional state of immune stress animals

By using β-glucan, yeast cell wall, and direct feeding of microorganisms and L-carnitine in pigs, the problem of insufficient vitamin A caused by immune stress in pigs is solved, and the growth performance and viability are improved, thus achieving the realization of the growth performance and viability. More efficient nutritional status recovery and health improvement.

CN119072239APending Publication Date: 2024-12-03ELANCO US INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202280091453.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-12-17
Filing Date
2022-12-19
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

In the commercial pig farming industry, pigs have insufficient vitamin A levels due to immune stress, which affects growth rate and survival rate. The prior art is difficult to effectively overcome this challenge by increasing the supply of dietary nutrients.

Method used

Using a composition containing beta-glucan, yeast cell wall, direct feeding microorganisms (yeast + DFM) and L-carnitine, the nutritional status of pigs is improved, vitamin A levels are restored, and growth performance is synergistically improved. Survival ability.

Benefits of technology

It effectively restores the pig's vitamin A level, improves growth performance and viability, reduces the negative impact of immune stress, and significantly improves the pig's feed conversion rate and health status.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072239A_ABST
    Figure CN119072239A_ABST
Patent Text Reader

Abstract

Disclosed are compositions comprising a composition comprising beta-glucan, yeast cell wall, direct feeding microorganism (yeast + DFM), and L-carnitine, and methods of using the composition for improving nutritional status, growth performance, and viability in an animal by administering the composition to the animal. Importantly, administration of yeast + DFM in combination with L-carnitine results in a synergistic recovery of insufficient circulating vitamin A levels in animals.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications This application claims priority to provisional application No. 63 / 290,876 filed on December 17, 2021, the entire contents of which are hereby incorporated herein by reference. Technical Field

[0002] Compositions for improving the nutritional status of animals and methods of using the compositions are disclosed. Background Art

[0003] As the human population is growing, the demand for food and food products from the livestock industry is expected to increase significantly.In commercial swine operations, faster growing animals are more profitable, and weight gain can be directly influenced by the nutritional status of the animal.

[0004] Specifically, in pigs, the nutritional status of retinol, as measured by serum concentrations of vitamin A, is positively correlated with growth rate and survival rate of suckling pigs before and after weaning. However, although dietary supplementation of nutrients such as vitamin A is sufficient based on nutritional requirements determined by the National Research Council (NRC; 2012), nutrient deficiencies still occur during immune challenges, including but not limited to physical, psychological and environmental stresses, viral infections such as PRRS, SIV, and bacterial infections such as E. coli and Salmonella. Pigs respond to these immune stresses by launching an immune response that transfers nutrients from growth to the immune system, and reducing feed consumption, which further reduces nutrient intake. These physiological responses lead to nutrient deficiencies during immune stress. Simply increasing dietary nutrient supply often cannot overcome these challenges.

[0005] To address these challenges, what is needed is a feed additive to restore vitamin A status and cancel the negative effects of up-regulating the immune system on growth and viability. Summary of the invention

[0006] One aspect of the present disclosure includes a method of improving the nutritional status of an immune stressed non-human animal in need thereof. The method includes orally administering to the animal a composition comprising β-glucan, yeast cell walls, a direct fed microbial (yeast+DFM), and L-carnitine, wherein improving the nutritional status of the animal includes restoring deficient circulating vitamin A levels in the animal to sufficient circulating vitamin A levels, and wherein administration of the yeast+DFM in combination with L-carnitine results in a synergistic restoration of deficient circulating vitamin A levels in the animal.

[0007] In some aspects, insufficient vitamin A levels are less than about 0.15 ppm, while sufficient vitamin A levels are about 0.15 ppm or more, about 0.15 ppm to about 0.2 ppm, or about 0.2 ppm or more.

[0008] The animal can be an animal that is immune stressed in response to a challenge. In some aspects, the animal is immune stressed in response to a stressor selected from microbial infection, induced inflammation (vaccination), psychological trauma (weaning), and physical trauma. In some aspects, the animal is immune stressed in response to weaning. In some aspects, the animal is immune stressed in response to vaccination.

[0009] The composition can be administered to the animal starting from weaning. In some aspects, administering yeast + DFM in combination with L-carnitine to the animal improves the growth performance and viability of the animal. In some aspects, growth performance includes ADG and feed conversion.

[0010] In some aspects, the animal is a pig. When the animal is a pig, the feed composition can include yeast, DFM, and L-carnitine at a ratio of about 89%, about 1%, and about 10% in the supplement, respectively. In some aspects, the composition is administered in the feed composition at an inclusion rate ranging from about 0.3 pounds per ton to about 0.6 pounds per ton or ranging from about 0.9 pounds per ton to about 1.1 pounds per ton.

[0011] Another aspect of the present disclosure includes methods of improving growth performance and viability of an animal in need thereof. The method includes orally administering to the animal a composition comprising beta-glucan, yeast cell walls, a direct-fed microbial (yeast+DFM), and L-carnitine, wherein improving growth performance and viability of the animal includes restoring deficient circulating vitamin A levels in the animal to sufficient circulating vitamin A levels, and wherein administration of yeast+DFM in combination with L-carnitine results in synergistic restoration of deficient circulating vitamin A levels in the animal. In some aspects, the animal is immunostressed.

[0012] Additional aspects of the disclosure include methods of reducing immune stress in an animal in need thereof. The method comprises orally administering to the animal a composition comprising beta-glucan, yeast cell walls, a direct-fed microbial (yeast+DFM), and L-carnitine, wherein reducing immune stress in the animal comprises restoring deficient circulating vitamin A levels in the animal to sufficient circulating vitamin A levels, and wherein administration of yeast+DFM in combination with L-carnitine results in synergistic restoration of deficient circulating vitamin A levels in the animal. In some aspects, the animal is immune stressed.

[0013] One aspect of the present disclosure includes a method for predicting the growth potential and viability of an animal. The method includes measuring the level of circulating vitamin A, correlating the level of circulating vitamin A with growth potential. The level of circulating vitamin A is positively correlated with growth potential and viability. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The patent or application file contains at least one drawing printed in color. Copies of the patent or patent application publication with one or more color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0015] Figure 1 Depicted is a graph showing serum vitamin A concentrations in pre-weaning and post-weaning pigs.

[0016] Figure 2 Depicted is a graph showing the correlation between serum vitamin A concentration and C-reactive protein at weaning.

[0017] Figure 3 Depicted is a graph showing changes in serum vitamin A concentrations in pre- and post-weaning pigs by dietary treatment.

[0018] Figure 4 Depicted is a graph showing the correlation between serum vitamin A and feed efficiency in growing pigs (60 to 200 pounds body weight (BW)).

[0019] Figure 5 Depicted is a graph showing the correlation between serum vitamin A and removal rate in growing pigs (60 to 200 pounds body weight).

[0020] Figure 6 Depicted is a graph showing the evolution of serum vitamin A concentrations in nursery pigs fed a composition of all or part of a beta-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination (Combo) from weaning to the end of the nursery phase. DETAILED DESCRIPTION

[0021] The present disclosure is based on the discovery that oral administration of a composition comprising β-glucan, yeast cell walls, direct-fed microorganisms (yeast+DFM), and L-carnitine to immune-stressed non-human animals improves the nutritional status, increases growth performance, and reduces mortality of immune-stressed non-human animals.

[0022] Importantly, the present inventors surprisingly found that administration of yeast + DFM in combination with L-carnitine to immune stressed non-human animals resulted in a synergistic improvement in the nutritional status, growth performance and viability of the animals. This was because animals fed yeast + DFM in combination with L-carnitine showed higher levels of improvement greater than would be expected by administration of yeast + DFM or L-carnitine alone.

[0023] I. Feed composition One aspect of the present disclosure includes a feed composition for non-human animals. The composition comprises a basic animal diet supplemented with a formulated yeast and "direct-fed microbial" (yeast + DFM) in combination with L-carnitine. The concentrations of yeast, DFM, and L-carnitine in the supplement are 89%, 1%, and 10%, respectively.

[0024] (a) Direct-fed microbial (DFM) As used herein, the term "direct-fed microbial" (DFM) is used to refer to probiotic or prebiotic live microorganisms that provide a health benefit when ingested by an animal. DFM may include yeast, bacteria, and combinations thereof.

[0025] As non-limiting examples, yeast DFMs may include Saccharomyces bisporus, Saccharomyces boulardii, Saccharomyces cerevisiae, Saccharomyces capsularis, Saccharomyces delbrueckii, Saccharomyces fermentati, Saccharomyces lugwigii, Saccharomyces microellipsoides, Saccharomyces pastorianus, Saccharomyces rosei, Candida albicans, Candida cloaceae, Candida tropicalis, Candida utilis, Geotrichum candidum, candidum, Hansenula americana, Hansenula anomala, Hansenula wingei, and Aspergillus oryzae.

[0026] Non-limiting examples of bacterial DFMs include Lactobacillus acidophilus, Bifedobact thermophilum, Bifidobact longhum, Streptococcus faecium, Bacillus pumilus, Bacillus subtilis, Bacillus licheniformis, Lactobacillus acidophilus, Lactobacillus casei, Enterococcus faecium, Bifidobacterium bifidium, Propionibacterium acidipropionici, Propionibacteriium freudenreichii, and Bifidobacterium scudolongum.

[0027] The amount of DFM in the feed composition can and will vary depending on the DFM, the type of non-human animal to which the feed composition is to be administered, the weight, sex and medical condition of the non-human animal, among other variables, and can be determined experimentally. Preferably, the DFM suitable for the feed composition of the present disclosure is Bacillus licheniformis. When the DFM of the feed composition is Bacillus licheniformis, the concentration of Bacillus licheniformis in the feed composition may range from about 1 x 10 1 cfu / g feed is about 1x10 10 cfu / g feed, about 1x 10 1 cfu / g feed is about 1x 10 6 cfu / g feed, about 1x 10 5 cfu / g feed is about 1x10 10 cfu / g feed or about 1x 10 3 cfu / g feed is about 1x 10 8 cfu / g feed. Preferably, the concentration of Bacillus licheniformis is about 1 x 10 4 About 1x 10 6 cfu / g feed.

[0028] (b) Formulated Yeast As used herein, the formulated yeast may comprise a combination of Saccharomyces cerevisiae yeast extract equivalent to about 25-100% by weight of the total formulated yeast, hydrolyzed yeast equivalent to about 0-40% by weight of the total formulated yeast, yeast culture equivalent to about 0-50% by weight of the total formulated yeast. The formulated yeast may also comprise limestone equivalent to about 0-50% by weight of the total formulated yeast.

[0029] The yeast prepared by the recipe can be any yeast, as long as the yeast is generally considered to be safe for use in food or medical applications. Non-limiting examples of yeast-derived products prepared by the recipe can include yeast cell wall-derived components, such as β-glucan, arabinoxylan isomaltose, agarooligosaccharides, lactosucrose, cyclodextrins, lactose, oligofructose, laminariheptaose, lactulose, β-galacto-oligosaccharides, mannanoligosaccharides, raffinose, stachyose, oligofructose, glucosylsucrose, sucrose thermo-oligosaccharides, isomaltulose, caramel, inulin and xylooligosaccharides. In one aspect, the yeast prepared by the recipe can be β-glucan and / or oligomannan. Sources of yeast cell wall-derived components include Saccharomyces bisporus, Saccharomyces boulardii, Saccharomyces cerevisiae, Saccharomyces capsulatus, Saccharomyces delkieri, Saccharomyces fermentans, Saccharomyces luwieri, Saccharomyces ellipsoides, Saccharomyces pastoriensis, Saccharomyces rosinensis, Candida albicans, Candida cloacae, Candida tropicalis, Candida utilis, Geotrichum candidum, Hansenula americana, Hansenula anomala, Hansenula wenchii, and Aspergillus oryzae.

[0030] The yeast prepared according to the recipe may also include bacterial cell wall derivatives, such as peptidoglycan and other components derived from gram-positive bacteria with high peptidoglycan content. Exemplary gram-positive bacteria include Lactobacillus acidophilus, Bifidobacterium thermophilum, Bifidobacterium longum, Streptococcus faecium, Bacillus brevis, Bacillus subtilis, Bacillus licheniformis, Lactobacillus acidophilus, Lactobacillus casei, Enterococcus faecium, Bifidobacterium bifidum, Propionibacterium acidipropionici, Propionibacterium freudenreichii, and Bifidobacterium pseudolongum.

[0031] The concentration of the formulated yeast in the feed composition of the present disclosure can and will vary depending on the formulated yeast, the type of non-human animal to which the feed composition is to be administered, the weight, sex, and medical condition of the non-human animal, among other variables, and can be determined experimentally. For example, the concentration of the formulated yeast in the feed composition can range from about 0.01 lb / ton of feed to about 1 lb / ton of feed, about 0.1 lb / ton of feed to about 2 lb / ton of feed, about 0.5 lb / ton of feed to about 1 lb / ton of feed, or about 0.1 lb / ton of feed to about 1 lb / ton of feed. In some aspects, the concentration of the capsicum product in the feed composition ranges from about 0.3 lb / ton of feed to about 1.0 lb / ton of feed.

[0032] (c) Basic animal diet The basal animal diet suitable for the feed compositions of the present disclosure can and will vary depending upon the intended animal, the weight of the animal, and the developmental stage of the animal, among other variables.

[0033] The terms "feed," "food," and "feed formula" are used interchangeably herein and may refer to any feed composition that is typically fed to animals. Basal animal diets that are typically fed to animals are known in the art. Basal animal diets may include one or more components of animal feed. Non-limiting examples of feed materials or animal feed materials may include, but are not limited to: corn or components of corn, such as, for example, corn meal, corn fiber, corn husks, corn DDGS (distiller's dried grain with solubles), silage, ground corn, corn germ, corn gluten, corn oil, or any other part of a corn plant; soybeans or components of soybeans, such as, for example, soybean oil, soybean meal, soybean husks, soybean silage, ground soybeans, or any other part of a soybean plant; wheat or any component of wheat, such as, for example, wheat flour, wheat fiber, wheat husks, wheat bran, or any other component of a corn plant. chaff), ground wheat, wheat germ or any other part of the wheat plant; rice or any component of rice, such as, for example, rice flour, rice fiber, rice hulls, rice bran, ground rice, rice germ or any other part of the rice plant; rapeseed, such as, for example, rapeseed oil, rapeseed meal, rapeseed protein, rapeseed hulls, ground rapeseed or any other part of the rapeseed plant; sunflower or components of the sunflower plant; sorghum or components of the sorghum plant; sugar beets or components of the sugar beet plant; sucrose or components of the sugar cane plant; barley or components of the barley plant; palm oil, palm kernel or components of the palm plant; glycerine; corn steep liquor; waste streams from agricultural processing plants; lecithin; rumen-protected fats; molasses; soy molasses; flax; peanuts; peas; oats; grasses, such as orchard grass The basal animal diet may be formulated for administration to any animal subject. The animal subject may be as described below.

[0034] The basal animal diet may optionally include at least one additional nutrient and / or pharmaceutical agent. For example, at least one additional nutrient and / or pharmaceutical agent may be selected from vitamins, minerals, amino acids, antioxidants, probiotics, essential fatty acids, and pharmaceutically acceptable excipients. The composition may include an additional nutrient and / or pharmaceutical component, or any of the aforementioned additional components in a combination of varying amounts. Suitable examples of each additional component are described in detail below.

[0035] A. Vitamins Optionally, the animal feed formulation may include one or more vitamins. Suitable vitamins for use in dietary supplements include vitamin C, vitamin A, vitamin E, vitamin B12, vitamin K, riboflavin, niacin, vitamin D, vitamin B6, folic acid, pyridoxine, thiamine, pantothenic acid, and biotin. The form of the vitamin may include a salt of the vitamin, a derivative of the vitamin, a compound with the same or similar activity as the vitamin, and a metabolite of the vitamin.

[0036] Animal feed formulas may include one or more forms of effective amounts of any vitamin described herein or otherwise known in the art. Exemplary vitamins include vitamin K, vitamin D, vitamin C, and biotin. An "effective amount" of a vitamin is generally quantified as an amount of at least about 10% of the U.S. recommended daily allowance ("RDA") for a particular vitamin described in the subject. However, it is expected that the amount of certain vitamins exceeding the RDA may be beneficial to certain animals. For example, the amount of a given vitamin may exceed the applicable RDA 100%, 200%, 300%, 400%, 500% or more.

[0037] B. Minerals Typically, animal feed formulations may include one or more minerals or mineral sources. Non-limiting examples of minerals include, but are not limited to, calcium, iron, chromium, copper, iodine, zinc, magnesium, manganese, molybdenum, phosphorus, potassium and selenium. Suitable forms of any of the aforementioned minerals include soluble mineral salts, slightly soluble mineral salts, insoluble mineral salts, chelated minerals, mineral complexes, non-reactive minerals (e.g., carbonyl minerals) and reduced minerals, and combinations thereof.

[0038] In general, animal feed formulas can include one or more forms of effective amounts of any mineral described herein or otherwise known in the art. The "effective amount" of a mineral is generally quantified as an amount of at least about 10% of the U.S. recommended daily intake ("RDA") of a particular mineral for a subject. However, it is expected that the amount of certain minerals exceeding the RDA may be beneficial to certain subjects. For example, the amount of a given mineral may exceed the applicable RDA 100%, 200%, 300%, 400%, 500% or more. Generally, the amount of the mineral included in the dietary supplement can range from about 1 mg to about 1500 mg, about 5 mg to about 500 mg, or about 50 mg to about 500 mg per dose.

[0039] C. Essential fatty acids Optionally, the animal feed formula can include a source of essential fatty acids. The essential fatty acids can be separated, or they can be an oil source or a fat source containing essential fatty acids. In one aspect, the essential fatty acids can be polyunsaturated fatty acids (PUFAs) having at least two carbon-carbon double bonds that are usually in a cis configuration. PUFAs can be long-chain fatty acids with at least 18 carbon atoms. PUFAs can be ω-3 fatty acids, wherein the first double bond occurs in the third carbon-carbon bond from the carbon chain methyl end (i.e., relative to the carboxylic acid group). Examples of ω-3 fatty acids include α-linolenic acid (18:3, ALA), stearidonic acid (stearidonic acid) (18:4), eicosatetraenoic acid (20:4), eicosapentaenoic acid (20:5; EPA), docosatetraenoic acid (22:4), n-3 docosapentaenoic acid (22:5; n-3DPA) and docosahexaenoic acid (22:6; DHA). PUFAs may also be ω-5 fatty acids, in which the first double bond occurs in the fifth carbon-carbon bond from the methyl end. Exemplary ω-5 fatty acids include myristoleic acid (14:1), myristoleate, and cetyl myristoleate. PUFAs may also be ω-6 fatty acids, in which the first double bond occurs in the sixth carbon-carbon bond from the methyl end. Examples of ω-6 fatty acids include linoleic acid (18:2), gamma-linolenic acid (18:3), eicosadienoic acid (20:2), dihomo-gamma-linolenic acid (20:3), arachidonic acid (20:4), docosadienoic acid (22:2), adrenic acid (22:4), and n-6 ​​docosapentaenoic acid (22:5). The fatty acid may also be an omega-9 fatty acid, such as oleic acid (18:1), eicosenoic acid (20:1), mead acid (20:3), sinapic acid (22:1), and nervonic acid (24:1).

[0040] On the other hand, the essential fatty acid source can be an oil derived from seafood. Seafood can be a vertebrate fish or a marine organism, so the oil can be a fish oil or a marine organism oil (marine oil). Long-chain (20C, 22C) ω-3 and ω-6 fatty acids are found in seafood. The ratio range of ω-3 fatty acids to ω-6 fatty acids in seafood is about 8:1 to 20:1. The seafood from which the oil rich in ω-3 fatty acids can be derived includes, but is not limited to, abalone scallops, albacore tuna, anchovies, catfish, clams, cod, gem fish, herring, lake trout (lake trout), mackerel, herring, orange roughy (orange roughy), salmon, sardines, mullet (sea mullet), sea bass (sea perch), shark, shrimp, squid, trout and tuna (tuna).

[0041] On the other hand, the essential fatty acid source can be a plant-derived oil. Plant and rapeseed oils are rich in omega-6 fatty acids. Some plant-derived oils, such as linseed oil, are particularly rich in omega-3 fatty acids. Plant or rapeseed oils are typically extracted from the seeds of the plant, but can also be extracted from other parts of the plant. Commonly used vegetable or vegetable oils for cooking or seasoning include, but are not limited to, acai oil, almond oil, amaranth oil, apricot seed oil, argan oil, avocado seed oil, babassu oil, ben oil, blackcurrant seed oil, Borneo tallow nut oil, borage seed oil, buffalo gourd oil, canola oil, carob pod oil, cashew oil, castor oil, coconut oil, cilantro seed oil, corn oil, cottonseed oil, evening primrose oil, false flax oil, linseed oil, grapeseed oil, hazelnut oil, hempseed oil, kapok seed oil, lallemantia oil, linseed oil, macadamia oil, The plant-derived oils may also be hydrogenated or partially hydrogenated.

[0042] In a further aspect, the source of essential fatty acids can be an algae-derived oil. Commercially available algae-derived oils include those from Crypthecodinium cohnii and Schizochytrium sp. Other suitable algae species from which oil may be extracted include Aphanizomenon flos-aquae, Bacilliarophy sp., Botryococcus braunii, Chlorophyceae sp., Dunaliella tertiolecta, Euglena gracilis, Isochrysis galbana, Nannochloropsis salina, Nannochloris sp., Neochlorisoleoabundans, Phaeodactylum tricornutum, Pleurochrysis carterae, Prymnesium parvum, Scenedesmus dimorphus, Spirulina sp. sp.) and Tetraselmis chui.

[0043] D. Amino Acids Animal feed formula can optionally comprise one to several amino acids.Suitable amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine or their hydroxy analogs.In some aspects, amino acid will be selected from essential amino acids.Essential amino acids are usually described as amino acids that biological de novo synthesis cannot be performed, and therefore must be provided in the diet.As non-limiting example, people's essential amino acids include: L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-valine and L-threonine.

[0044] E. Antioxidants Animal feed formulations may include one or more suitable antioxidants. As will be appreciated by those skilled in the art, the suitability of a given antioxidant will vary depending on the species to which the dietary supplement will be administered. Non-limiting examples of antioxidants include ascorbic acid and salts thereof, ascorbyl palmitate, ascorbyl stearate, anoxomer, N-acetylcysteine, benzyl isothiocyanate, anthranilic acid, m-aminobenzoic acid or p-aminobenzoic acid (o is anthranilic acid, p is PABA), butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), caffeic acid, canthaxanthin, alpha-carotene, beta-carotene, beta-carotene, beta-apo-carotenoic acid, beta-carotene ... acid), carnosol, carvacrol, catechins, cetyl gallate, chlorogenic acid, citric acid and its salts, p-coumaric acid, curcurin, 3,4-dihydroxybenzoic acid, N,N'-diphenyl-p-phenylenediamine (DPPD), dilauryl thiodipropionate, distearyl thiodipropionate, 2,6-di-tert-butylphenol, dodecyl gallate, ethylenediaminetetraacetic acid, ellagic acid, isoascorbic acid, sodium isoascorbate, esculetin, esculin, 6-ethoxy-1,2-dihydro-2,2,4-trimethylquinone phenoxyethanol, ethyl gallate, ethyl maltol, ethylenediaminetetraacetic acid (EDTA), eugenol, ferulic acid, flavonoids, flavonoids (e.g., apigenin, chrysin, luteolin), flavonols (e.g., genistein, myricetin, daemfero), flavanones, quercetin, fumaric acid, gallic acid, gentian extract, gluconic acid, glycine, guaiac gum, hesperetin, α-hydroxybenzylphosphinic acid, hydroxycinnamic acid, hydroxyglutaric acid, hydroquinone, N-hydroxysuccinic acid, hydroxytyrosol, hydroxyurea, lactic acid and its salts, lecithin, lecithin citrate; R-α-lipoic acid, lutein, lycopene, malic acid, maltol, 5-methoxytryptamine, methyl gallate, monoglyceride citrate; monoisopropyl citrate;Morin, beta-naphthoflavone, nordihydroguaiaretic acid (NDGA), octyl gallate, oxalic acid, palmityl citrate, phenothiazine, phosphatidylcholine, phosphoric acid, phosphates, phytic acid, phytylubichromel, propyl gallate, polyphosphates, quercetin, trans-resveratrol, rosmarinic acid, sesamol, silymarin, sinapinic acid, succinic acid, octadecyl citrate, syringic acid, tartaric acid, thymol, tocopherols (i.e., α-, β-, γ-, and δ-tocopherol), tocotrienols (i.e., α-, β-, γ-, and δ-tocotrienol), p-hydroxyphenylethanol, vanillic acid, 2,6-di-tert-butyl-4-hydroxymethylphenol (i.e., ionoxime 100), 2,4-(tri-3',5'-di-tert-butyl-4'-hydroxybenzyl)-trimethylbenzene (i.e., Ionox 330), 2,4,5-trihydroxybutyrophenone, ubiquinone, tert-butylhydroquinone (TBHQ), thiodipropionic acid, trihydroxybutyrophenone, tryptamine, tyramine, uric acid, vitamin K and derivatives, vitamin Q10, zeaxanthin, or a combination thereof. ;

[0045] Natural antioxidants that may be included in the dietary supplement include, but are not limited to, apple peel extract, blueberry extract, carrot juice powder, clove extract, coffee berry, coffee bean extract, cranberry extract, eucalyptus extract, ginger powder, grape seed extract, green tea, olive leaf, parsley extract, peppermint, bell pepper extract, pomace, pomegranate extract, rice bran extract, rose hips, rosemary extract, sage extract, tart cherry extract, tomato extract, turmeric, and wheat germ oil.

[0046] F. Anti-inflammatory agents Animal feed formulations may optionally include at least one anti-inflammatory agent. In one aspect, the anti-inflammatory agent may be a synthetic nonsteroidal anti-inflammatory drug (NSAID), such as acetylsalicylic acid, dichlophenac, indomethacin, oxamethacin, ibuprofen, indoprofen, naproxen, ketoprofen, mefamanic acid, analgin, piroxicam and celecoxib. In alternative aspects, the anti-inflammatory agent may be a prohormone that regulates the inflammatory process. Suitable prohormones with the properties include prohormone convertase 1, proopiomelanocortin, prohormone B-type natriuretic peptide, SMR1 prohormone, etc. In another aspect, the anti-inflammatory agent may be an enzyme with anti-inflammatory effects. Examples of anti-inflammatory enzymes include bromelain, papain, serrapeptidase and proteolytic enzymes such as pancreatin (a mixture of trypsin, amylase and lipase).

[0047] In still another aspect, the anti-inflammatory agent can be a peptide having an anti-inflammatory effect. For example, the peptide can be an inhibitor of phospholipase A2, such as antiflammin-1, a peptide corresponding to amino acid residues 246-254 of lipocortin; antiflammin-2, a peptide corresponding to amino acid residues 39-47 of uteroglobin; S7 peptide, which inhibits the interaction between interleukin 6 and interleukin 6 receptor; RP1, a prenyl protein inhibitor; and similar peptides. On the other hand, the anti-inflammatory peptide can be cortistatin (a cyclic neuropeptide related to somatostatin) or a peptide corresponding to the N-terminal fragment of the SV-IV protein, the conserved region of E-selectin, L-selectin and P-selectin, etc. Other suitable anti-inflammatory preparations include collagen hydrolysates and milk micronutrient concentrates (e.g., available from Stolle Milk Biologics, Inc., Cincinnati, OH). ), as well as milk protein hydrolysates, casein hydrolysates, whey protein hydrolysates and plant protein hydrolysates.

[0048] In a further aspect, the anti-inflammatory agent can be a probiotic that has been shown to regulate inflammation. Suitable immunomodulating probiotics include lactic acid bacteria, such as acidophilli, lactobacillus and bifidophilli. In yet another aspect, the anti-inflammatory agent can be a plant extract with anti-inflammatory properties. Non-limiting examples of suitable plant extracts with anti-inflammatory benefits include blueberry, boswella, black tea and skullcap, celery seed, chamomile, cherry, devil's sclaw, eucalyptus, evening primrose, ginger, hawthorn berry, horsetail, Kalopanax pictusbark, licorice root, turmeric, white wallow, willow bark and yucca.

[0049] G. Herbs The animal feed formulation may optionally comprise at least one herb or herb derivative. Suitable herbs and herb derivatives as used herein refer to herbal extracts, and materials derived from plants and plant parts, such as leaves, flowers and roots, but are not limited thereto. Non-limiting exemplary herbs and herbal derivatives include agrimony, alfalfa, aloe, amaranth, angelica, fennel, barberry, basil, bayberry, bee pollen, birch, bistort, blackberry, black cohosh, black walnut, blessed thistle, blue cohosh, blue verbena, eupatorium, borage, buchu, buckthorn, prunella vulgaris, burdock, capsicum, pepper, caraway, cascara, catnip, celery, cornflower, chamomile, chasteberry, chickweed, chicory, cinchona, clove, coltsfoot, comfrey, corn silk, thatch, viburnum, Virginia herb clematis, cyani, cornflower, turner grass, dandelion, hookweed, angelica, echinacea, elecampane, ephedra, eucalyptus, evening primrose, eyebright, false lily ... unicorn), fennel, fenugreek, figwort, flaxseed, garlic, gentian, ginger, Korean ginseng, goldenseal, bengal, gum grass, hawthorn, hops, horehound, horseradish, horsetail, polygonum multiflorum, hydrangea, hyssop, Iceland moss, Irish moss, jojoba, juniper, large brown kelp, lady's slipper, lemongrass, licorice, lobelia, mandrake, marigold, marjoram, marshmallow, mistletoe, mullein, mustard, myrrh, nettle, oat straw, Oregon grape, papaya, parsley, passionflower, peach, mint, peppermint, periwinkle, plantain grass, willow-leaf milkweed, American pokeweed, American pepper, plantain, quercetin, zedoary, red clover, raspberry, redmondclay, rhubarb, rose hip, rosemary, rue, safflower, saffron, sage, hypericum perforatum, sarsaparilla, sassafras, saw palmetto, skullcap, polygala, senna, shepherd's purse, slippery elm, spearmint, spikenard, twin-fruit vine, Chinese tallow tree, strawberry, tahipur, thyme, bearberry, valerian, violet, watercress, white oak bark, white pine bark, wild cherry, wild lettuce, wild yam, willow, deer hoof grass, witch hazel, pedicularia, wormwood, yarrow, yellow sorrel, santa, yucca, and combinations thereof.

[0050] H. pigment The animal feed formulation may optionally include at least one pigment. Suitable non-limiting pigments include erythrocyanidin, alizarin, isoflavone, β-apo-2'-carotene aldehyde, apo-2-lycopene aldehyde, apo-6'-lycopene aldehyde, astaxanthin, astaxanthin, scrophulariaceae aldehyde, bacteriocyanidin, aixin, α-carotene, β-carotene, γ-carotene, β-carotene, canthaxanthin, capsanthin, capsanthin, citrus peel carotenoids, citrus lutein, crocin, crocin, crocin semialdehyde, crocin, chitosan, cryptocapsanthin, α-cryptoxanthin, β-cryptoxanthin, cryptomonaxanthin (cryptomonaxa nthin), combaxanthin, decaprenylxanthin, dehydroanthraquinone, diatomaxanthin, 1,4-diamino-2,3-dihydroanthraquinone, 1,4-dihydroxyanthraquinone, 2,2'-diketospiraxanthin, foliachrome, fucoxanthin, phytofluoxanthin, hopkinsiaxanthin, hydroxyspheriodenone, isofucoxanthin, chlorophycin, lutein, xanthophyll lycopene, phytoene, lycopene, phytofluanin, quinone, zeaxanthin, neokron, neolutein, nonaprenoxanthin, OH-chlorobacterene, oxaloxanthin, paracentrone, pectenolone, comb xanthin, peridinin, mycobacterium phleifolium lutein, phoeniconone, phoenicopterone, phoenicoxanthin, phytofluanin, hexahydrophytoopene, pyrrhoxanthinol, quinones, rhodoxanthin B, rhodoxanthin, rhodoxanthin, rhodoxanthin, rhodoxanthin, rhodoxanthin, rhodoxanthin, half-α-carotene ketone, half-β-carotene ketone, sintaxanthin, fucoxanthin, fucoxanthin, spherulene, fucoxanthin, rhodoxanthin, rhodoxanthin methyl ester, toruloxanthin aldehyde, toruloxanthin, 1,2,4-trihydroxyanthraquinone, smelaxanthin, nasturtium pigment, aphroxanthin, violaxanthin, wamingone, madderxanthin, zeaxanthin, α-zeaxanthin or a combination thereof.

[0051] I. Pharmaceutically acceptable agents The animal feed formulation may optionally include at least one pharmaceutically acceptable agent. Suitable non-limiting pharmaceutically acceptable agents include acid / base labile drugs, pH dependent drugs, or drugs that are weak acids or weak bases. Examples of acid labile drugs include statins (e.g., pravastatin, fluvastatin, and atorvastatin), antibiotics (e.g., penicillin G, ampicillin, streptomycin, erythromycin, clarithromycin, and azithromycin), nucleoside analogs (e.g., dideoxyinosine (ddI or didanosine), dideoxyadenosine (ddA), dideoxycytosine (ddC), salicylates (e.g., aspirin), digoxin, bupropion, pancreatin, midazolam, and methadone. Drugs that are soluble only at acidic pH include nifedipine, emopride, nicardipine, amosulalol, noscapine, propranolol, quinine, dipyridamole, josamycin, dilevolol, labetalol, iniprost, and metronidazole. Drugs that are weak acids include phenobarbital, phenytoin, zidovudine (AZT), salicylates (e.g., aspirin), propionic acid compounds (e.g., ibuprofen), indole derivatives (e.g., indomethacin), phenanthenate Compounds (e.g., meclofenamic acid), pyrrolidine acid compounds (e.g., tolmetin), cephalosporins (e.g., cephalothin, cephalexin, cefazolin, cephradine, cefpirin, cefmandol, and cefoxitin), 6-fluoroquinolones, and prostaglandins. Drugs that are weak bases include adrenergic drugs (e.g., ephedrine, methamphetamine, phenylephrine, epinephrine, salbutamol, and terbutaline), cholinergic drugs (e.g., physostigmine and neostigmine), and acetaminophen. ), antispasmodics (e.g., atropine, ethantheline, and papaverine), curare-like agents (e.g., chlorisothiazine), tranquilizers and muscle relaxants (e.g., fluphenazine, thioridazine, trifluoperazine, chlorpromazine, and triflupromazine), antidepressants (e.g., amitriptyline and nortriptyline), antihistamines (e.g., diphenhydramine, chlorpheniramine, dimenhydrinate, tripelennamine, perphenazine, chlorproxazine, and chlorpheniramine), cardioactivators (e.g., verapamil, diltiazem, In one aspect, the drug can be bisphosphonates or another drug for the treatment of osteoporosis. The non-limiting examples of bisphosphonates include alendronate, ibandronate, risedronate, zoledronate, pamidronate, neridronate, olpadronate, etidronate, clodronate and tiludronate. Other suitable drugs include estrogen, selective estrogen receptor modulators (SERMs) and parathyroid hormone (PTH) drugs. In another aspect, the drug can be an antibacterial agent. Suitable antibiotics include aminoglycosides (e.g., amikacin, gentamicin, kanamycin, neomycin, nethimycin, streptomycin, and tobramycin), carbacephems (e.g., loracarbef), carbapenems (e.g., ertapenem, imipenem, and meropenem), cephalosporins (e.g., cefoperazone, cefazolin, cephalexin, cefaclor, cefmandole, cefuroxime, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftriaxone, and ceftriaxone), macrolides (e.g., azithromycin, clarithromycin, dirithromycin, erythromycin, and troleandomycin), ), monobactams, penicillins (e.g., amoxicillin, ampicillin, carbenicillin, cloxacillin, dicloxacillin, nafcillin, oxacillin, penicillin G, penicillin V, piperacillin, and ticarcillin), polypeptides (e.g., bacitracin, colistin, and polymyxin B), quinolones (e.g., ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomifloxacin, moxifloxacin, norfloxacin, ofloxacin, and trovafloxacin), sulfonamides (e.g., mafenide, sulfacetamide, sulfamethoxazole, sulfasalazine, sulfisoxazole, and trimethoprim-sulfamethoxazole), and tetracyclines (e.g., demeclocycline, doxycycline, minocycline, and oxytetracycline). In alternative aspects, the drug can be an antiviral protease inhibitor (e.g., amprenavir, fosamprenavir, indinavir, lopinavir / ritonavir, ritonavir, saquinavir, and nelfinavir). In still another aspect, the drug can be a cardiovascular drug. Examples of suitable cardiovascular drugs include cardiotonic agents (e.g., digitalis (digoxin), ubidecarenone, and dopamine), vasodilators (e.g., nitroglycerin, captopril, dihydralazine, diltiazem, and sirolimus). and isosorbide dinitrate), antihypertensive agents (e.g., alpha-methyldopa, chlorthalidone, reserpine, reserpine ethyl, resermine, prazosin, phentolamine, felodipine, propranolol, pindolol, labetalol, clonidine, captopril, enalapril, and lisinopril), beta-blockers (e.g., levobunolol, pindolol, timolol maleate, bisoprolol, carvedilol, and butoxamine), alpha-blockers (e.g., doxazosin, prazosin, phenoxybenzamine, phentolamine, tamsulosin, alfuzosin, and terazosin), calcium channel blockers (e.g., alodipamine, felodipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, lacidipine, lercanidipine, verapamil, gallopamil, and diltiazem ), monensin, bacitracin, salinomycin, narasin, diclaserol, tylosin, bacitracin, bacitracin zinc salt, and anticoagulants (e.g., dipyridamole).

[0052] J. excipient A variety of common excipients in animal feed formulations can be selected based on compatibility with the active ingredient. Non-limiting examples of suitable excipients include agents selected from the group consisting of non-effervescent disintegrants, colorants, flavor improvers, oral dispersants, stabilizers, preservatives, diluents, compacting agents, lubricants, fillers, binders, taste masking agents, effervescent disintegrants, and combinations of any of these agents.

[0053] In one aspect, the excipient is a binder. Suitable binders include starch, pregelatinized starch, gelatin, polyvinyl pyrrolidone, cellulose, methylcellulose, sodium carboxymethyl cellulose, ethyl cellulose, polyacrylamide, polyvinyl oxazolidinone, polyvinyl alcohol, C12-C18 fatty acid alcohol, polyethylene glycol, polyol, sugar, oligosaccharides, polypeptide, oligopeptides and combinations thereof. Polypeptide can be any arrangement of amino acids ranging from about 100 to about 300,000 daltons.

[0054] In another aspect, the excipient can be a filler. Suitable fillers include carbohydrates, inorganic compounds and polyvinyl pyrrolidone. As non-limiting examples, fillers can be dibasic and tribasic calcium sulfate, starch, calcium carbonate, magnesium carbonate, microcrystalline cellulose, calcium hydrogen phosphate, magnesium carbonate, magnesium oxide, calcium silicate, talc, modified starch, lactose, sucrose, mannitol and sorbitol.

[0055] Excipients may include non-effervescent disintegrants. Suitable examples of non-effervescent disintegrants include starches such as corn starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays such as bentonite, microcrystalline cellulose, alginates, sodium starch glycolate, gums such as agar, guar gum, locust bean gum, karaya gum, pectin, and tragacanth.

[0056] In another aspect, the excipient can be an effervescent disintegrant. As non-limiting examples, suitable effervescent disintegrants include sodium bicarbonate in combination with citric acid and sodium bicarbonate in combination with tartaric acid.

[0057] The excipients may include a preservative. Suitable examples of preservatives include antioxidants, such as alpha-tocopherol or ascorbate, and antimicrobials, such as parabens, chlorobutanol or phenol.

[0058] In another aspect, the excipient may include a diluent. Suitable diluents for use include pharmaceutically acceptable sugars such as sucrose, dextrose, lactose, microcrystalline cellulose, fructose, xylitol, and sorbitol; polyols; starch; preformed direct compression diluents; and mixtures of any of the above substances.

[0059] Excipients may include flavorings. Flavorings incorporated into the outer layer may be selected from synthetic flavoring oils and flavoring aromatics and / or natural oils, extracts from plants, leaves, flowers, fruits, and combinations thereof. As examples, these may include cinnamon oil, wintergreen oil, peppermint oil, clover oil, hay oil, anise oil, eucalyptus, vanilla extract, citrus oils such as lemon oil, orange oil, grape and grapefruit oils, fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.

[0060] In another aspect, the excipient may include a sweetener. As non-limiting examples, the sweetener may be selected from glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; stevia (stevioside); chlorine derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, Sylitol, etc.

[0061] In another aspect, the excipient can be a lubricant. Suitable non-limiting examples of lubricants include magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and light mineral oil.

[0062] The excipient may be a dispersion enhancer. Suitable dispersants may include starch, alginic acid, polyvinyl pyrrolidone, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicates and microcrystalline cellulose as a high HLB emulsifier surfactant.

[0063] Depending on the aspect, it may be desirable to provide a colorant in the outer layer. Suitable color additives include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C) or external drug and cosmetic colors (Ext. D&C). Depending on the aspect, these colors or dyes and their corresponding lakes and certain natural and derived colorants may be suitable for use in the present invention.

[0064] Excipients may include taste masking agents. Taste masking materials include, for example, cellulose hydroxypropyl ether (HPC), such as Nisswo HPC and PrimaFlo HP22; low-substituted hydroxypropyl ether (L-HPC); cellulose hydroxypropyl methyl ether (HPMC), such as Seppifilm-LC, Metolose SR, Opadry YS, PrimaFlo, MP3295A, Benecel MP824 and Benecel MP843; methylcellulose polymers such as and Ethyl cellulose (EC) and its mixtures, such as E461, Surelease; polyvinyl alcohol (PVA), such as Opadry AMB; hydroxyethyl cellulose, such as Carboxymethyl cellulose and salts of carboxymethyl cellulose (CMC), such as Polyvinyl alcohol and polyethylene glycol copolymers, such as Kollicoat Monoglycerides (Myverol), triglycerides (KLX), polyethylene glycol, modified food starch, acrylic acid polymers, and mixtures of acrylic acid polymers and cellulose ethers, such as EPO, RD100 and E100; cellulose acetate phthalate; sepifilms, such as a mixture of HPMC and stearic acid, cyclodextrins, and mixtures of these materials. In other aspects, contemplated additional taste masking materials are those described in U.S. Patent Nos. 4,851,226, 5,075,114, and 5,876,759, each of which is hereby incorporated by reference in its entirety.

[0065] In various aspects, the excipient may include a pH adjuster. In certain aspects, the pH adjuster may include sodium carbonate or sodium bicarbonate.

[0066] The amounts and types of ingredients (ie, metal chelates, chondroprotectants, vitamins, minerals, amino acids, antioxidants, yeast cultures, and essential fatty acids) and other excipients useful in animal feed formulations are described throughout the specification and in the examples.

[0067] II. Feed Additive Composition One aspect of the present disclosure includes a feed additive composition for non-human animals. The composition comprises a basic animal diet supplemented with formulated yeast and "direct-fed microorganisms" (yeast + DFM) in combination with L-carnitine. Other optional additives may be further included. The feed additive composition may be added to a basic animal diet for administration to non-human animals. The feed additive composition may be formulated with a basic animal diet to prepare the feed composition described in Section I.

[0068] The amount of the formulated yeast in the feed additive composition can and will vary depending on the formulated yeast, the type of non-human animal to which the feed additive composition comprising the formulated yeast will be administered, the weight, sex, and medical condition of the non-human animal to which the feed additive composition will be administered. Typically, the feed additive composition may contain about 30% to about 95% of the formulated yeast, about 40% to about 90% of the formulated yeast, or about 55% to about 90% of the formulated yeast. In some aspects, the feed additive composition may contain about 88% to about 90%, or about 89%.

[0069] The amount of DFM in the feed additive composition of the present disclosure may range from about 0.05% to about 15%, about 0.1% to about 10%, about 0.5% to about 5%, about 0.9% to about 1.1%. In some aspects, the amount of DFM in the feed additive composition of the present disclosure ranges from about 0.9% to about 1.1%.

[0070] The amount of L-carnitine in the feed additive composition of the present disclosure is 10%, about 1% to about 20%, about 5% to about 15%, about 7% to about 13%, about 9% to about 11%. In some aspects, the amount of L-carnitine in the feed additive composition of the present disclosure ranges from about 9% to about 11%.

[0071] In various aspects, the feed additive composition can be introduced into the basic animal diet by various methods, depending on whether the feed additive composition is in liquid or solid form. Non-limiting examples of introducing the feed additive composition into the basic animal diet can be formulating the feed additive composition into the basic animal diet, surface treating a solid composition of the basic animal diet, spraying the liquid feed additive composition onto the basic animal diet, or a combination thereof. It will be appreciated that when the feed additive is introduced into the basic animal diet, the amount of the feed additive introduced into the basic animal diet is sufficient to provide a therapeutically effective amount of the formulated combination of yeast and Capsicum product in the diet of the animal.

[0072] In addition to the yeast product, DFM and L-carnitine, the feed additive composition may further comprise at least one additional ingredient, such as vitamins, minerals, amino acids, antioxidants, probiotics other than those that may be present in the DFM, essential fatty acids and pharmaceutically acceptable excipients. Such ingredients may be as described in Section 1(e) above. In some aspects, the feed additive composition further comprises rice hulls, mineral oil and calcium stearate.

[0073] III. How to use Another aspect of the present disclosure includes methods of using feed compositions. The method includes applying the animal feed composition or feed additive of the present disclosure to a non-human animal. In some aspects, the feed or feed additive composition is orally administered to a non-human animal. The feed composition may be as described in section (I) above, and the feed additive composition may be as described in section (II) above.

[0074] In some aspects, non-human animals are immune stressed. As used herein, the term "immune stressed animal" refers to a non-human animal that is stressed in response to inflammation, or stressors such as microbial infection, induced inflammation such as due to vaccination, psychological trauma such as weaning and physical trauma together with other stressors. Immune stressed animals typically have insufficient nutritional status, as measured by insufficient circulating vitamin A. Stressors and vitamin A deficiencies can lead to reduced growth performance and increased mortality in animals. Therefore, in some aspects, the method of the present disclosure includes improving the nutritional status of non-human animals with immune stress. In some aspects, the method of the present disclosure includes improving the growth performance and viability of animals. In some aspects, the method of the present disclosure includes reducing inflammation in animals.

[0075] The time control and duration of administering the composition of the present disclosure to an animal can and will vary. The feed composition can be administered during the entire time period of feeding the animal. On the other hand, the feed composition can be administered during a specific time period during the growth and development of the animal. For example, the feed composition can be administered during a time period of increased susceptibility of the animal to infection, such as during infancy. The composition can also be administered after a microbial infection is detected and for the duration of the infection. The composition can also be administered at various time intervals. For example, the composition can be administered once a day, once a week, once a month, or over several months. In some aspects, the composition is administered once a week. In other aspects, the composition is administered once a month. In some aspects, the composition is administered once a day. As will be appreciated in the art, the duration of treatment can and will vary depending on the growth and health of the animal.

[0076] (a) Non-human animals In a broad sense, non-human animals can be defined as any animal that shows improved growth, improved health, improved intestinal health and reduced microbial pathogen counts after applying the feed additive composition. In various aspects, non-human animals can be livestock mammals of different ages and health. Non-limiting examples of suitable livestock mammals can be beef cattle, horses, dairy cows, calves, pigs, goats, sheep, bison, llamas or alpacas. In other aspects, non-human animals can be avian species of different ages and health. Non-limiting examples of suitable avian species or poultry can be chickens, including chickens and breeders (ratites) of tender chickens, laying eggs, ducks, game hens (game hens), geese, pheasants, guinea fowl / hens, quails, turkeys, and ratites (ratites), such as emus and ostriches and aquaculture. On the other hand, non-human animals can be companion animals of different ages and health. Non-limiting examples of companion animals can be dogs, cats, birds, hamsters or guinea pigs. In some aspects, the non-human animal is selected from a growing pig, a calf, a foal, a kid, a lamb, a cria, a chicken, a turkey, a duckling, a puppy, a kitten, or a combination thereof. In some aspects, the non-human animal is a pig. In some aspects, the non-human animal is an immune stressed pig. In some aspects, the non-human animal is an immune stressed nursery pig.

[0077] (b) Improved performance In some aspects, the method includes using a feed additive to improve the performance of an animal. "Improved performance" as defined herein refers to a positive change in size and / or maturity of a non-human animal over a period of time. In various aspects, the non-human animal exhibits improved growth performance, including, for example, an increase in weight gain, feed intake, average daily weight gain (ADG), a decrease in feed conversion ratio (FCR), an increase in average daily food intake (ADFI), improved total body weight and F / G ratio, wherein the F / G ratio is defined as ADFI / ADG.

[0078] Compared to a control group not supplemented with the feed additive composition, the non-human animal can show a reduction in feed conversion rate ranging from about 2% to about 5%, about 2% to about 5%, or about 3.0% or more. Compared to a control group not supplemented with the feed additive composition, the non-human animal can show a reduced mortality rate ranging from about 0.5% to about 10%, about 1% to about 8%, about 1% to about 5%, or at least 2.0% or more. Compared to a control group not supplemented with the feed additive composition, the non-human animal can show improved weight gain, as defined as a percentage increase ranging from about 1% to about 10%, about 3% to about 5%, or at least 3.0%.

[0079] (c) Improved health Still another aspect of the present disclosure includes methods for improving the health of non-human animals. "Improved health" as defined herein refers to a reduction in the incidence of diarrhea, a reduction in the number of days with diarrhea, a reduction in mortality, improved intestinal health, a reduction in microbial pathogens in the intestinal tract of an animal, a reduction in cytokine panel measurement of TNF-α, a reduction in immunocrit levels, or a combination thereof in a non-human animal compared to a control group.

[0080] (d) Reduced impact of microbial pathogens Still another aspect of the present disclosure includes methods for reducing the impact of microbial pathogens in non-human animals. Reducing the impact of microbial pathogens can include improving intestinal health and reducing microbial pathogens in non-human animals. Reducing the impact of microbial pathogens can also include improving the overall health and performance of non-human animals exposed to microbial pathogens.

[0081] As defined herein, the term "microbial pathogen" refers to a microorganism that has the potential to cause disease. An infection is the invasion and proliferation of pathogenic microorganisms within a subject. Disease is when an infection causes damage to a vital function or system of the subject.

[0082] "Improved intestinal health" and "reduction of microbial pathogens" refer to a reduction in the number of pathogens and a reduction in inflammation caused by microbial pathogens in a non-human animal compared to a control group. Non-limiting examples of pathogenic bacteria that can be controlled using the feed additive compositions of the present disclosure include Clostridium perfringen, Eimeria maxima, Aeromonas hydrophila, Yersinia enterocolitica, Vibrio spp., Leptospira spp., Mycobacterium ulcerans, Listeria spp., pathogenic strains of E. coli, Pseudomonas spp. such as Pseudomonas aeruginosa, Enterococcus spp., Salmonella spp., Campylobacter spp., Staphylococcus spp. spp.) such as Staphylococcus epidermidis, S. aureus (MRSA), M. smegmatis, Streptococcus sp., Clostridia, and M. marinum.

[0083] In preferred alternative aspects of the aspects, reducing the impact of microbial pathogens comprises reducing the impact of Clostridium perfringens in young chickens. In alternative aspects of the aspects, reducing the impact of microbial pathogens comprises controlling necrotic enteritis in chickens. In another alternative aspect, reducing the impact of microbial pathogens comprises controlling the impact of Clostridium perfringens in combination with a coccidiosis challenge in disease-challenged young chickens.

[0084] definition Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs. The following references provide general definitions of many terms used in the present invention for those skilled in the art: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd edition 1994); The Cambridge Dictionary of Science and Technology (Walker, 1988); The Glossary of Genetics, 5th edition, R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, unless otherwise specified, the following terms have the meanings assigned to them.

[0085] When introducing elements of the present disclosure or one or more preferred aspects thereof, the articles "a," "an," "the," and "said" are intended to mean that there are one or more of the elements. The terms "comprising," "including," and "having" are intended to be inclusive and mean that there may be additional elements besides the listed elements.

[0086] As various changes could be made in the above cells and methods without departing from the scope of the invention, it is intended that all matter contained in the above description and examples given below shall be interpreted as illustrative and not in a limiting sense. Example

[0087] All patents and publications mentioned in this specification are indicative of the levels of ordinary technicians in the field to which the present disclosure belongs. All patents and publications are incorporated herein by reference to the same extent as if each publication was specifically and individually indicated to be incorporated by reference.

[0088] The publications discussed throughout are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such disclosure by virtue of prior invention.

[0089] The following examples are included to demonstrate the present disclosure. It will be appreciated by those skilled in the art that the techniques disclosed in the following examples represent techniques that the inventors have discovered to function well in the practice of the present disclosure. However, based on the present disclosure, it will be appreciated by those skilled in the art that many changes may be made to the present disclosure without departing from the spirit and scope of the present disclosure and still obtaining the same or similar results, and therefore all matters stated should be interpreted as illustrative rather than limiting.

[0090] Example 1. Feeding a β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination (Combo) increases circulating vitamin A concentrations and improves growth performance in post-weaned nursery pigs A study was conducted to evaluate the effect of feeding a β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination. A total of 36 pens were used in the study, with 27 mixed-sex pigs per pen. Pigs were weighed on arrival on a pen-by-pen basis. Pens were blocked by weight and pens within blocks were randomly assigned to one of three dietary treatments in a randomized complete block design, resulting in 12 pens per treatment (Table 1).

[0091] Table 1. Dietary treatments The analysis of Combo indicated that the concentrations of β-glucan, total glucan and mannose were not less than 5.7%, 10.0% and 9.0% respectively, and the concentration of DFM was not less than 7.5×108 cfu / g product.

[0092] The trial was conducted on a 4-phase feeding program for 49 days immediately after weaning. The composition of the commercial control diet is shown in Table 2. Feed was The system provides for collection of feed intake data by pen.

[0093] Pigs were weighed on a pen basis upon arrival and when most pens had completed each phase. On the same day that the pigs were weighed, feed residues were also measured for each pen. The data of the system are used to calculate ADG, ADFI and F / G for each pig pen.

[0094] Blood samples were collected from two pigs per pen at four time points: two days before weaning in the sow unit, day 0 (just after weaning), day 7, and day 48 in the nursery unit. Serum samples were stored at -20°C until analysis. Subjective fecal scores were measured for each pen on days 3, 5, and 7 of nursery using a scale of 0 = none; 1 = mild; 2 = considerable; 3 = severe signs of diarrhea.

[0095] result: Part 1. Preweaning vaccination and weaning reduce circulating vitamin A concentrations Vaccinations (PRRS / PCV2 / Mycoplasma) received by pigs two days before weaning combined with stress from the weaning process resulted in a 27% decrease (P<0.001) in serum vitamin A concentrations on the day of weaning ( Figure 1 ). On day 48 after weaning, serum vitamin A concentrations gradually returned to similar levels observed 2 days before weaning.

[0096] Inadequate serum vitamin levels are often considered a symptom of dietary / nutrient deficiencies. However, this is not always the case. In the examples described and below, vitamin A was supplemented as retinyl acetate to provide 8,819.4 IU / kg of vitamin A in the diet, which is 4 times the required vitamin A concentration for 5 to 25 kg nursery pigs (2,200 IU / kg) as described by the National Research Council (NRC; 2012). The data suggest that serum vitamin A concentrations at weaning are negatively correlated with serum C-reactive protein (CRP), one of the major acute phase proteins elevated in serum as a result of challenge in pigs ( Figure 2 ).

[0097] Part 2. Restoration of circulating vitamin A concentrations after weaning by feeding a β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination As pigs recover from immune stress after weaning, circulating vitamin A concentrations gradually return to levels similar to those measured before weaning ( Figure 3 Data from a subset of sampled pigs indicated that pigs fed a diet containing the β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination (Combination) had a maximum increase in serum vitamin A concentration from weaning to day 7 post-weaning (38.4%) and from weaning to day 48 post-weaning (64.3%; Table 3), respectively, compared to pigs fed the control and yeast + DFM treatments.

[0098] The increase in serum vitamin A concentration from weaning in pigs fed the yeast + DFM treatment was moderate (25.8% and 60.1%, respectively). In addition, pigs fed the Combo treatment had 20% significantly higher nursery ADG compared to pigs fed the control diet (0.76 vs. 0.64 lb / day, P=0.01), while pigs fed the yeast + DFM treatment only had a modest improvement in pig ADG (0.73 vs. 0.64 lb / day, P=0.10).

[0099] Table 3. Effects of feeding a β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination (Combo) on serum vitamin A concentrations in pre-weaned and post-weaned pigs (values ​​shown are least square means) a,b Mean values ​​without common superscripts are different (P<0.05) c,d Means without a common superscript tend to be different (P < 0.10) The distribution of serum vitamin A was also evaluated. Although pigs assigned to the Combo treatment started with the lowest percentage of pigs (95%) with sufficient vitamin A (>=0.15 ppm) before weaning, feeding Combo in the nursery resulted in the highest percentage of pigs (95.2%) with sufficient vitamin A at the end of the 49-day nursery period compared to the control and yeast + DFM treatments (95.0% and 91.7%, respectively, Table 4). On day 48, serum CRP concentrations in pigs fed Combo were also 21% lower than those fed the control diet (368.3 vs. 467.5 μg / ml, P=0.10; Table 3). These data suggest that dietary supplementation of Combo effectively restores circulating vitamin A concentrations after weaning, which indicates maximal recovery from the immune stress caused by weaning. Table 4. Distribution of serum vitamin A concentrations before and after weaning by dietary treatment *Based on the reference from R. Plus, 1994, vitamin A insufficiency was defined as serum vitamin A concentration < 0.15 ppm, while vitamin A sufficiency was defined as serum vitamin A concentration >= 0.15 ppm.

[0100] Part 3. Correlation between circulating vitamin A concentrations and growth performance in pigs Linear correlation analyses were performed to evaluate the correlation between serum vitamin A concentrations measured before and after weaning and growth performance (ADG and BW) of individual pigs during the nursery period. In 24 pairs of correlation analyses, numerical or significant positive correlations were determined (Table 5). In particular, serum vitamin A at weaning was positively correlated with ADG and BW of pigs throughout the nursery period. Pig body weight at the end of the nursery period was positively correlated with serum vitamin A before and after weaning (P<0.052). The large number of positive correlations between serum vitamin A and ADG / BW of pigs suggests that circulating vitamin A may be performance indicative.

[0101] Table 5. Correlation between serum vitamin A concentration and pig growth performance Part 4. Feeding a β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination (Combo) improves growth performance and survivability of post-weaning nursery pigs As shown in Table 6, when all pig performance data were analyzed, feeding a nursery diet containing Combo resulted in significantly higher pig ADG and BW at the end of the 49-day nursery period compared to pigs fed the control diet (0.69 vs. 0.65 lb / day, P<0.05, 45.5 vs. 43.4 lbs, P<0.05, respectively). Pigs fed yeast + DFM had intermediate ADG and BW that were not significantly different from pigs fed the control treatment. In addition, pigs fed Combo and yeast + DFM showed lower mortality compared to those fed the control treatment (1.85 vs. 3.41%). Pigs fed Combo also tended to require fewer individual antibiotic treatments compared to those fed the control diet (6.5 vs. 10.5%, P<0.10). These results suggest that feeding the Combo diet improves growth performance and survival of post-weaned pigs.

[0102] Example 2. Feeding β-glucan / yeast cell wall / direct-fed microorganisms / L-carnitine combination (Combo) improves feed efficiency in growing pigs An 11-week study was conducted to evaluate the effects of feeding Combo and yeast + DFM to a group of immune-stressed growing pigs on growth performance and viability. This group of immune-stressed pigs is characterized by PRRS and SIV positive, with relatively high mortality and morbidity than their production standards. Upon arrival, pigs (~35 pounds) were sorted into pens, 17-26 pigs per pen, and gender balance was maintained as much as possible. Pigs were fed a normal diet until the start of the trial about 2 to 3 weeks later. On the first day of the experiment, the pens were weighed and divided into groups according to the average body weight, and the pens within the blocks were randomly assigned to one of the three dietary treatments (Table 7) in a randomized complete block design. This resulted in 11 pens for each treatment for evaluating growth performance and health status.

[0103] Table 7. Dietary treatments Pigs were weighed per pen every 2 weeks (+ / - 1 day) except at the barn top and between runs out. Feed residues were measured when each pen was weighed. This allowed calculation of ADG, ADFI and F / G per pen. The composition of the basal diet is shown in Table 8.

[0104] Blood samples were collected prior to the start of the trial as baseline measurements from two average-sized barrows per pen. These sampled pigs were tagged for subsequent bleeding on days 32 and 76 after the start of the trial. Serum samples were stored at -20°C until vitamin A analysis was performed.

[0105] Table 8. Dietary composition of the control diet (Treatment 1).

[0106] result: Part 1. Feeding a β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination (Combo) improves feed efficiency and survivability in immune-stressed growing pigs Results from Table 9 show that pigs fed Combo had a 5 point reduction in F / G at market compared to those fed Control (2.22 vs. 2.27, P=0.28). However, pigs fed Yeast + DFM did not show any effect on feed efficiency. In addition, feeding Combo tended to reduce mortality (0.82 vs. 2.98%, P=0.09) and significantly reduced total elimination rate in health-compromised pigs (2.47 vs. 2.98%, P=0.04) compared to those fed Control diet. These results suggest that feeding Combo improves feed efficiency and survivability in immune-stressed growing pigs.

[0107] Table 9. Effect of feeding β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination (Combo) on growth performance of growing pigs under immune stress project Comparison Combo Yeast + DFM PSE P-value Number of pig pens 11 11 11 Number of pigs 235 243 223 Starting weight, pounds 61.5 61.8 62.0 1.2 0.59 ADG, lb / day 1.93 1.92 1.93 0.02 0.77 ADFI, lb / day 4.22 4.23 4.31 0.05 0.40 F / G 2.27 2.22 2.28 0.03 0.35 Weight at the end of week 11, pounds 213.4 210.7 212.3 1.5 0.44 mortality rate,% 2.98c <![CDATA[0.82 d ]]> <![CDATA[0.90 cd ]]> N / A 0.11 Total removal, % <![CDATA[6.38 a ]]> <![CDATA[2.47 b ]]> <![CDATA[4.04 ab ]]> N / A 0.12 a,b Mean values ​​without common superscripts are different (P<0.05) c,d Means without a common superscript tend to be different (P < 0.10) Part 2. Feeding a β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination (combination) improves circulating vitamin A concentrations, which is associated with better pig performance

[0104] Serum vitamin A concentrations were evaluated in 22 sampled pigs per treatment on day 0 (baseline), day 32 and day 76 of the experiment (Table 10). Feeding the Combo numerically increased serum vitamin A concentrations by 0.9% and 4.1% on day 32 and day 76, respectively, compared to the control. However, feeding yeast + DFM had no improvement or a moderate improvement.

[0108] Table 10. Effect of feeding a β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination (Combo) on serum vitamin A concentrations in immune-stressed growing pigs Serum vitamin A concentration, ppm Comparison Combo Yeast + DFM PSE P-value Number of samples 22 22 22 <![CDATA[Serum vitamin A - D0 (baseline) 1 > 0.180 0.186 0.188 0.008 0.77 Serum Vitamin A-D32 0.191 0.193 0.191 0.010 0.98 Serum Vitamin A-D76 0.197 0.205 0.202 0.009 0.78 1 Baseline vitamin A concentration was used as a covariate for the analysis of vitamin A concentrations at day 32 and day 76.

[0109] A general linear model was performed using the mean values ​​of F / G at market, total excretion, and serum vitamin A from each treatment. Serum vitamin A on day 32 was negatively correlated with pig F / G and could be used to predict pig F / G using the following equation ( Figure 4 ): F / G (60 to 200 pounds body weight) = -26.096 x serum vitamin A (day 32) + 7.2606, where R2 = 0.99 Serum vitamin A at day 76 was negatively correlated with elimination and can be used to predict total elimination in pigs using the following equation ( Figure 5 ): Total removal rate (%) = -480.75 × serum vitamin A (76th day) + 101.26, where R2 = 1.00 The strong linear correlation and predictability of serum vitamin A between pig F / G and elimination rate suggest that serum vitamin A may be a performance indicator in immune stressed growing pigs. Feeding Combo improved feed conversion, nutritional status and health status of immune stressed pigs.

[0110] Example 3. Dose response of feeding β-glucan / yeast cell wall / direct-fed microorganism / L-carnitine combination (Combo) to nursery and growing pigs To evaluate the dose response of feeding Combo to nursery pigs, high (1.0 lb / ton) and low (0.5 lb / ton) dietary concentrations of Combo were fed to newly weaned pigs in the study described in Example 1. For relatively healthier nursery pigs without major health issues, feeding Combo at a lower dose of 0.5 lb / ton resulted in better growth performance (Table 11) and greater increases in serum vitamin A after weaning (Table 12) compared to feeding Combo at a higher dose of 1.0 lb / ton. Feeding Combo at a higher dose showed moderate improvements compared to feeding the control treatment.

[0111] To evaluate the dose response of feeding Combo to growing pigs, high (1.0 lb / ton) and low (0.5 lb / ton) dietary concentrations of Combo were fed to growing pigs in the study described in Example 2. In immune stressed growing pigs, feeding Combo at a lower dose of 0.5 lb / ton resulted in better feed efficiency and survivability compared to feeding Combo at a higher dose of 1.0 lb / ton (Table 13). The dose response of feeding Combo in nursery and growing pigs may depend on the health and immune status of the pigs. Table 11. Effects of feeding high (1.0 lb / ton) and low (0.5 lb / ton) dietary concentrations of β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combinations on growth performance in nursery pigs a, b have no common superscripts and the mean values ​​are different (P<0.05) c, d The means without common superscripts tend to be different (P < 0.10) Table 1 Effects of feeding high (1.0 lb / ton) and low (0.5 lb / ton) dietary concentrations of β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combinations (Combo) on serum vitamin A concentrations in pre-weaned and post-weaned pigs (values ​​shown are least squares means) a,b Mean values ​​without common superscripts are different (P<0.05) c,d Means without a common superscript tend to be different (P < 0.10)

[0112] Table 13. Effects of feeding high (1.0 lb / ton) and low (0.5 lb / ton) dietary concentrations of β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combinations (Combo) on growth performance of immune-stressed growing pigs a,b Mean values ​​without common superscripts are different (P<0.05) c,d Means without a common superscript tend to be different (P < 0.10) Example 4. Feeding the entire components of the β-glucan / yeast cell wall / direct-fed microorganism / L-carnitine combination (Combo) results in better growth performance, survival, and increased circulating vitamin A concentrations compared to feeding the partial components to nursery pigs weighing 8 to 45 pounds. To evaluate the effect of dietary supplementation with the entire components of the β-glucan / yeast cell wall / direct-fed microorganism / L-carnitine combination (Combo) versus the partial components, a study was designed to feed the dietary treatments shown in Table 14 to nursery pigs weighing approximately 8 to 45 pounds after weaning. Specifically, a total of 216 mixed-sex pigs were randomly placed into pens at weaning, with 27 pigs per pen. The pens were block-grouped according to weaning weight, and the pens within the blocks were randomly assigned to one of the four dietary treatments, resulting in two pens for each treatment. The study was conducted immediately after weaning for 65 days on a 4-stage feeding program. The composition of the basal diet is shown in Table 15. Vitamin A was supplemented as retinyl acetate in a vitamin and trace mineral premix to provide 8,819.4 IU / kg of vitamin A in the diet, which is four times the required vitamin A concentration (2,200 IU / kg) for 5 to 25 kg nursery pigs as stated by the National Research Council (NRC; 2012).

[0113] Combo analysis indicated that the concentrations of β-glucan, total glucan and mannose were not less than 5.7%, 10.0% and 9.0%, respectively. The concentration of DFM was not less than 7.5×108 cfu / g product. If included in the diet, the dietary concentrations of β-glucan, yeast cell wall, DFM and carnitine were the same for each treatment.

[0114] Table 14. Dietary treatments Table 15. Dietary composition of the basal diet Serum samples were collected from two randomly selected pigs per pen at weaning (before access to the experimental diet) and at the end of the nursery period when the pigs reached a body weight of approximately 45 lbs. Serum samples were analyzed for vitamin A concentration.

[0115] Figure 6Results in (1994) showed that the mean serum vitamin A concentration at weaning was 0.08 ppm, which is 47% lower than the adequate level of serum vitamin A described by R. Puls (1994) (0.15 ppm). The inadequate nutritional vitamin A status at weaning may be attributed to the immune stress experienced by the pigs during the weaning process. Pigs fed Combo had the highest serum vitamin A concentration at the end of nursery (0.541 ppm) compared to pigs fed control (0.461 ppm), yeast / DFM (0.491 ppm) or carnitine (0.503 ppm). The percentage increase in serum vitamin A concentration from weaning to the end of nursery was 117%, 72%, 114% and 140% for control, yeast / DFM, carnitine and Combo, respectively ( Figure 6 ). In addition, feeding Combo also showed the greatest improvement in serum vitamin A concentration range (0.175-0.189 ppm) at the end of the nursery period compared to all other treatments (Table 16). Except for the Combo treatment, the lowest serum vitamin A concentration at the end of the nursery period for the other 3 treatments was below the adequate level of 0.15 ppm, suggesting that despite the pigs being fed a vitamin A-sufficient diet, they still developed vitamin A deficiency. These results suggest that dietary supplementation with Combo provided the greatest restoration of nutritional status of vitamin A after weaning compared to the control, yeast / DFM, and carnitine treatments.

[0116] Table 16. Minimum, maximum and mean serum vitamin A concentrations in nursery pigs at the end of the weaning and nursery periods Restoring the nutritional status of vitamin A by feeding Combo to newly weaned pigs resulted in a synergistic effect on growth performance and survival rate compared to feeding partial components of Combo. The results from Table 17 suggest that feeding the full components of Combo resulted in 129% and 108% greater nursery-to-market ADG and market-to-market G / F, respectively, compared to the control. These improvements were greater than the additive effects of feeding yeast / DFM (79% and 41%, respectively) or carnitine (29% and 29%, respectively) alone. In addition, pigs fed the full components of Combo also showed the lowest mortality rate (P=0.14) compared to pigs fed partial components of Combo and control treatments. Improvements in survival rate appear to be greatest during the first 22 days after weaning, when the nutritional status of circulating vitamin A is low due to immune stress at weaning ( Figure 6 ).

[0117] Table 17. Effects of feeding a β-glucan / yeast cell wall / direct-fed microbial / L-carnitine combination (Combo) or its individual components on growth performance and survival of nursery pigs weighing 8 to 45 pounds The data in Table 18 suggest that feeding a diet containing Combo from 12 to 53 pounds of body weight to weaned pigs at an inclusion level of 0.5 pounds per ton of feed consistently and repeatedly improves growth performance and survival of pigs. Specifically, in each of the three studies, the nursery ADG of pigs fed Combo increased by an average of 4.1% (0.76 vs. 0.73 pounds per day; P<0.10) compared to the control in the meta-analysis. In 2 of the 3 studies, nursery feed conversion increased by an average of 1.2% (1.59 vs. 1.61; P=0.81) compared to the control. The greater ADG of pigs fed Combo resulted in an average of 1.3 pounds heavier nursery weights at market compared to the control (P=0.03). In addition, total pig removals (dead and laggard pigs combined) were reduced from 12.9% to 10.6% (P=0.19) and medically treated pigs were reduced from 19.0% to 15.7% (P=0.10) in the Combo treatment compared to the control. The meta-analysis suggests that feeding Combo consistently and repeatedly improves survival and growth performance in nursery pigs weighing 12 to 53 pounds. These beneficial effects in nursery pigs may be driven by restored vitamin A nutritional status after weaning, as shown in the previous examples.

Claims

1. A method of improving the nutritional status of an immune stressed non-human animal in need thereof, the method comprising orally administering to the animal a composition comprising β-glucan, yeast cell walls, a direct fed microbial (yeast+DFM), and L-carnitine, wherein improving the nutritional status of the animal comprises restoring deficient circulating vitamin A levels in the animal to sufficient circulating vitamin A levels, and wherein administration of the yeast+DFM in combination with L-carnitine results in a synergistic restoration of deficient circulating vitamin A levels in the animal.

2. The method of claim 1, wherein the insufficient vitamin A level is less than about 0.15 ppm and the sufficient vitamin A level is about 0.15 ppm or more, about 0.15 ppm to about 0.2 ppm, or about 0.2 ppm or more.

3. The method of claim 1, wherein the animal is an immunologically stressed animal in response to a challenge.

4. The method of claim 1, wherein the animal is immunologically stressed in response to a stressor selected from the group consisting of microbial infection, induced inflammation (vaccination), psychological trauma (weaning), and physical trauma.

5. The method of claim 1, wherein the animal is immunologically stressed in response to weaning.

6. The method of claim 1, wherein the animal is immunologically stressed in response to vaccination.

7. The method of claim 3, wherein the composition is administered to the animal starting from weaning.

8. The method of claim 1, wherein administering yeast + DFM in combination with L-carnitine to the animal improves the growth performance and viability of the animal.

9. The method of claim 1, wherein the growth performance comprises ADG and feed conversion.

10. The method of claim 1, wherein the animal is a pig.

11. The method according to claim 1, wherein the feed composition comprises yeast, DFM, L-carnitine in a ratio of about 89%, about 1%, about 10% respectively in the supplement.

12. The method of claim 1, wherein the composition is administered in the feed composition at an inclusion rate ranging from about 0.3 lbs / ton up to about 0.6 lbs / ton or at an inclusion rate ranging from about 0.9 lbs / ton up to about 1.1 lbs / ton.

13. A method of improving growth performance and viability of an animal in need thereof, the method comprising orally administering to the animal a composition comprising β-glucan, yeast cell walls, a direct fed microbial (yeast+DFM), and L-carnitine, wherein improving growth performance and viability of the animal comprises restoring deficient circulating vitamin A levels in the animal to sufficient circulating vitamin A levels, and wherein administration of yeast+DFM in combination with L-carnitine results in a synergistic restoration of deficient circulating vitamin A levels in the animal.

14. The method of claim 13, wherein the animal is immunologically stressed.

15. A method of reducing immune stress in an animal in need thereof, the method comprising orally administering to the animal a composition comprising β-glucan, yeast cell walls, a direct fed microbial (yeast+DFM), and L-carnitine, wherein reducing immune stress in the animal comprises restoring deficient circulating vitamin A levels in the animal to sufficient circulating vitamin A levels, and wherein administration of the yeast+DFM in combination with L-carnitine results in a synergistic restoration of deficient circulating vitamin A levels in the animal.

16. The method of claim 15, wherein the animal is immunologically stressed.

17. A method for predicting the growth potential and viability of an animal, the method comprising measuring the level of circulating vitamin A, correlating the level of circulating vitamin A with growth potential, wherein the level of circulating vitamin A is positively correlated with growth potential and viability.

Citation Information

Cited By

  • Fructus cannabis protein peptide capable of improving brain and physical fatigue and preparation method and application of fructus cannabis protein peptide

    CN122303364A